Visen Pharmaceuticals Announces First Time Detailed Clinical Data From Phase 3 Trial Of Lonapegsomatropin
Visen Pharmaceuticals, An Innovative Biopharmaceutical Company Focused On Endocrine Diseases, Has Announced For The First Time Detailed Clinical Data From Its Pivotal Phase 3 Study Of Lonapegsomatropin, A Long-Acting Prodrug Of Unmodified Somatropin Being Investigated As A Once-Weekly Injection In Children With Growth Hormone Deficiency (Ghd) In China.The Data Showed That Lonapegsomatropin Demonstrated An Annualized Height Velocity (Ahv) Of 10.66 Cm/Year Compared To 9.75 Cm/Year For The Daily Hgh At 52 Weeks (Treatment Difference At 0.91 Cm/Year With A 95 Per Cent Confidence Interval: 0.37
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
